









Markets
/
Stocks
/
nasdaq-xgn
/

Exagen Inc

XGN

3.510USD

+0.150+4.46%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

79.01MMarket Cap

LossP/E TTM



Exagen Inc

3.510

+0.150+4.46%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Exagen Inc

Currency: USD Updated: 2026-02-06

Key Insights

Exagen Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 39 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.29.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Exagen Inc's Score

Industry at a Glance

Industry Ranking

39 / 75

Overall Ranking

194 / 4521

Industry

Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Exagen Inc Highlights

StrengthsRisks

Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 22.12% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 55.64M.

Fairly Valued

The company’s latest PE is -3.75, at a medium 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 790.01K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.96.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

13.286

Target Price

+295.41%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Exagen Inc is 7.40, ranking 48 out of 75 in the Healthcare Providers & Services industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 17.24M, representing a year-over-year increase of 37.87%, while its net profit experienced a year-over-year increase of 40.95%.

Score

Industry at a Glance

Previous score

7.40

Change



Financials

7.76

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.14

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.91

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.02

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.15

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Exagen Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Exagen Inc is 7.51, ranking 27 out of 75 in the Healthcare Providers & Services industry. Its current P/E ratio is -3.75, which is -79.26% below the recent high of -0.78 and -256.99% above the recent low of -13.39.

Score

Industry at a Glance

Previous score

7.51

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 39/75

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Exagen Inc is 8.50, ranking 11 out of 75 in the Healthcare Providers & Services industry. The average price target is 15.00, with a high of 18.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

13.286

Target Price

+295.41%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Exagen Inc

XGN

CVS Health Corp

CVS

Teladoc Health Inc

TDOC

HCA Healthcare Inc

HCA

Tenet Healthcare Corp

THC

Universal Health Services Inc

UHS

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Exagen Inc is 6.73, ranking 44 out of 75 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 5.73 and the support level at 2.30, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.66

Change

0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.047

Sell

RSI(14)

22.489

Sell

STOCH(KDJ)(9,3,3)

11.040

Oversold

ATR(14)

0.344

High Vlolatility

CCI(14)

-92.516

Neutral

Williams %R

89.017

Oversold

TRIX(12,20)

-2.042

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

3.584

Sell

MA10

3.833

Sell

MA20

4.467

Sell

MA50

5.828

Sell

MA100

8.133

Sell

MA200

7.904

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Exagen Inc is 5.00, ranking 49 out of 75 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 58.04%, representing a quarter-over-quarter increase of 3.67%. The largest institutional shareholder is The Vanguard, holding a total of 790.01K shares, representing 3.49% of shares outstanding, with 27.45% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Tullis Health Investors

1.81M

NMSIC Co-Investment Fund, L.P

1.76M

-16.60%

RTW Investments L.P.

1.70M

H.I.G. Capital, LLC

1.70M

Hunt Holdings, L.P

829.28K

-18.00%

The Vanguard Group, Inc.

Star Investors

733.82K

+7.66%

Balyasny Asset Management LP

723.43K

+0.65%

Invesco Capital Management LLC

Star Investors

675.19K

+12257.10%

Kennedy Capital Management LLC

551.85K

+77.60%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Exagen Inc is 4.56, ranking 47 out of 75 in the Healthcare Providers & Services industry. The company's beta value is 1.89. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Exagen Inc’s latest ESG disclosure leads the Healthcare Providers & Services industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.